33 days after the bacterial challenge, a single subcutaneous injection of mycobacteriophage D29 reduced pathology and prevented the development of ulcers. This protection significantly reduced the number of M. ulcerans, increased levels of cytokines (including IFN-), and generated a lymphocytic/macrophage-profiled cellular infiltration. The gene discussed is IFNA1; the disease is ulcer disease.